Want to see SE:DPHA full AI Analyst Report?
Total Valuation
Guard Therapeutics International AB has a market cap or net worth of kr62.33M. The enterprise value is -kr1.84.
Market Capkr62.33M
Enterprise Value-kr1.84
Share Statistics
Guard Therapeutics International AB has 44,588,066 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding44,588,066
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Guard Therapeutics International AB’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee―
Profits Per Employee―
Employee Count12
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of Guard Therapeutics International AB is ―. Guard Therapeutics International AB’s PEG ratio is 0.00813.
PE Ratio―
PS Ratio0.00
PB Ratio0.65
Price to Fair Value―
Price to FCF-0.24
Price to Operating Cash Flow―
PEG Ratio0.00813
Income Statement
In the last 12 months, Guard Therapeutics International AB had revenue of ― and earned ― in profits. Earnings per share was ―.
Revenue―
Gross Profit―
Operating Income―
Pretax Income―
Net Income―
EBITDA―
Earnings Per Share (EPS)―
Cash Flow
In the last 12 months, operating cash flow was ― and capital expenditures ―, giving a free cash flow of ― billion.
Operating Cash Flow―
Free Cash Flow―
Free Cash Flow per Share―
Dividends & Yields
Guard Therapeutics International AB pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.42
52-Week Price Change-93.84%
50-Day Moving Average1.49
200-Day Moving Average1.47
Relative Strength Index (RSI)47.96
Average Volume (3m)44.15K
Important Dates
Guard Therapeutics International AB upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Guard Therapeutics International AB as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, Guard Therapeutics International AB has paid ― in taxes.
Income Tax―
Effective Tax Rate―
Enterprise Valuation
Guard Therapeutics International AB EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Guard Therapeutics International AB has ― in cash and marketable securities with kr0.00 in debt, giving a net cash position of ― billion.
Cash & Marketable Securities―
Total Debtkr0.00
Net Cash―
Net Cash Per Share―
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for Guard Therapeutics International AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast70.76%